Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics.

Ma VT, Boonstra PS, Menghrajani K, Perkins C, Gowin KL, Mesa RA, Gotlib JR, Talpaz M.

Clin Lymphoma Myeloma Leuk. 2018 May;18(5):e201-e210. doi: 10.1016/j.clml.2018.02.019. Epub 2018 Mar 2.

2.

The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia.

Alcasid M, Ma L, Gotlib JR, Arber DA, Ohgami RS.

Int J Lab Hematol. 2017 Apr;39(2):129-136. doi: 10.1111/ijlh.12594. Epub 2017 Jan 30.

PMID:
28133918
3.

Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry.

Chisholm KM, Merker JD, Gotlib JR, Gitana G, Lefterova M, Zehnder JL, George TI, Arber DA, Ohgami RS.

Am J Clin Pathol. 2015 Apr;143(4):527-34. doi: 10.1309/AJCPZ3J4GEEYIRRA.

PMID:
25780004
4.

Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis.

Sasaki K, Gotlib JR, Mesa RA, Newberry KJ, Ravandi F, Cortes JE, Kelly P, Kutok JL, Kantarjian HM, Verstovsek S.

Leuk Lymphoma. 2015 Jul;56(7):2092-7. doi: 10.3109/10428194.2014.984703. Epub 2015 Feb 17.

5.

Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.

Ohgami RS, Ma L, Merker JD, Gotlib JR, Schrijver I, Zehnder JL, Arber DA.

Mod Pathol. 2015 May;28(5):706-14. doi: 10.1038/modpathol.2014.160. Epub 2014 Nov 21.

6.

Acute myeloid leukemia with monosomal karyotype: morphologic, immunophenotypic, and molecular findings.

Weinberg OK, Ohgami RS, Ma L, Seo K, Ren L, Gotlib JR, Seetharam M, Cherry A, Arber DA.

Am J Clin Pathol. 2014 Aug;142(2):190-5. doi: 10.1309/AJCPMLO84JDNVLNK.

PMID:
25015859
7.

Altered translation of GATA1 in Diamond-Blackfan anemia.

Ludwig LS, Gazda HT, Eng JC, Eichhorn SW, Thiru P, Ghazvinian R, George TI, Gotlib JR, Beggs AH, Sieff CA, Lodish HF, Lander ES, Sankaran VG.

Nat Med. 2014 Jul;20(7):748-53. doi: 10.1038/nm.3557. Epub 2014 Jun 22.

8.

Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22).

Johnson RC, Savage NM, Chiang T, Gotlib JR, Cherry AM, Arber DA, George TI.

Am J Clin Pathol. 2013 Oct;140(4):525-35. doi: 10.1309/AJCP1Q0YSXEAHNKK.

PMID:
24045550
9.

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.

Pollyea DA, Zehnder J, Coutre S, Gotlib JR, Gallegos L, Abdel-Wahab O, Greenberg P, Zhang B, Liedtke M, Berube C, Levine R, Mitchell BS, Medeiros BC.

Haematologica. 2013 Apr;98(4):591-6. doi: 10.3324/haematol.2012.076414. Epub 2012 Dec 14.

10.

Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.

Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, O'Hare T, Druker BJ, Loriaux MM.

Cancer Res. 2013 Jan 1;73(1):285-96. doi: 10.1158/0008-5472.CAN-12-1906. Epub 2012 Oct 18.

11.

DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups.

Ohgami RS, Ma L, Ren L, Weinberg OK, Seetharam M, Gotlib JR, Arber DA.

Br J Haematol. 2012 Oct;159(2):182-90. doi: 10.1111/bjh.12029. Epub 2012 Aug 28.

PMID:
22924777
12.

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.

Pollyea DA, Kohrt HE, Gallegos L, Figueroa ME, Abdel-Wahab O, Zhang B, Bhattacharya S, Zehnder J, Liedtke M, Gotlib JR, Coutre S, Berube C, Melnick A, Levine R, Mitchell BS, Medeiros BC.

Leukemia. 2012 May;26(5):893-901. doi: 10.1038/leu.2011.294. Epub 2011 Oct 28.

PMID:
22033493
13.

Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Liedtke M, Twist CJ, Medeiros BC, Gotlib JR, Berube C, Bieber MM, Bhat NM, Teng NN, Coutre SE.

Haematologica. 2012 Jan;97(1):30-7. doi: 10.3324/haematol.2011.045997. Epub 2011 Oct 11.

14.

Treatment advances have not improved the early death rate in acute promyelocytic leukemia.

McClellan JS, Kohrt HE, Coutre S, Gotlib JR, Majeti R, Alizadeh AA, Medeiros BC.

Haematologica. 2012 Jan;97(1):133-6. doi: 10.3324/haematol.2011.046490. Epub 2011 Oct 11.

15.

Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors.

Pollyea DA, Raval A, Kusler B, Gotlib JR, Alizadeh AA, Mitchell BS.

Hematol Oncol. 2011 Sep;29(3):157-60. doi: 10.1002/hon.976. Epub 2010 Oct 27. No abstract available.

PMID:
21922510
16.

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A.

J Clin Oncol. 2011 Mar 1;29(7):789-96. doi: 10.1200/JCO.2010.32.8021. Epub 2011 Jan 10.

17.

RNAi screen for rapid therapeutic target identification in leukemia patients.

Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O'Hare T, Heinrich MC, Druker BJ.

Proc Natl Acad Sci U S A. 2009 May 26;106(21):8695-700. doi: 10.1073/pnas.0903233106. Epub 2009 May 11.

18.

Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens.

Fan AC, Deb-Basu D, Orban MW, Gotlib JR, Natkunam Y, O'Neill R, Padua RA, Xu L, Taketa D, Shirer AE, Beer S, Yee AX, Voehringer DW, Felsher DW.

Nat Med. 2009 May;15(5):566-71. doi: 10.1038/nm.1903. Epub 2009 Apr 12.

Supplemental Content

Loading ...
Support Center